Drugs of abuse tests require highly selective, robust assays. Aptamers are helping to deliver new assays for more sensitive and simpler tests. According to the UN Office on Drugs…

Toni Rogers and David Bunka of Aptamer Group examine the latest tools and assays to address small molecule targets and deliver faster, cheaper and better diagnostics in this feature…

Anti-hapten antibodies are difficult and slow to generate limiting cheap and efficient bioanalysis in this field. Our proprietary methods offer standard assay formats, such as ELISA and lateral flow…

Antibiotic resistance is increasing globally and represents one of the biggest public health challenges of our time. In the US alone, there are more than 2.8 million cases of…

In the recently published paper in Talenta from Dr Mark Platt and the team at Loughborough University, they demonstrate a novel approach for aptamer biosensors to detect…

A universal aptamer-based sensing strategy is proposed using DNA modified nanocarriers and Resistive Pulse Sensing (RPS) for the rapid (≤20 min) and label free detection of small molecules. The surface…

In this work, a surface plasmon resonance (SPR)-based assay for the quantification of antineoplastic drug irinotecan in human plasma samples has been developed for the first time. The selective…

Watch as Dr David Bunka, Aptamer Group CTO, details how BLI is used within Aptamer Group’s screening and validation processes to identify the best aptamer and Optimer™ reagents, with…

A newly published paper in The Analyst by Dr. Federico Polo, Assistant Professor at Ca’ Foscari University of Venice and former group leader at the National…

The anticancer drug imatinib is often involved in therapeutic drug monitoring (TDM) studies aimed at improving the treatment of several forms of leukemia and gastrointestinal stromal tumors (GIST). To…